General Cardiac Technology
Focus: General Cardiac Technology is a publicly traded biotechnology company focused on cardiovascular solutions, including sternum support harnesses and investigational drugs for intracerebral hemorrhage. Founded in 2018 and headquartered in San Jose, CA, the company operates in a narrow, specialized cardiac segment.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About General Cardiac Technology
AI assessmentNot HiringNo open roles listed right now. Follow General Cardiac Technology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Aspirin 75 mg daily
Intracerebral HaemorrhageTranexamic acid injection
Intracerebral Hemorrhagic StrokeOpen Jobs (0)
Help build intelligence for General Cardiac Technology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.